Aizawa K, Tanaka N, Yabusaki H, Suzuki S, Muto I, Nishimaki T, Suzuki T, Hatakeyama K, Tanaka O
First Department of Surgery, Niigata University School of Medicine, Japan.
Surg Oncol. 1995 Jun;4(3):139-45. doi: 10.1016/s0960-7404(10)80018-0.
We established two xenografts of small-cell carcinoma (SCC) arising in the oesophagus or the stomach, designated TEG13 and TSG15, and investigated the responses to experimental chemotherapy on these strains. Both tumours were classified as the intermediate cell type of SCC composed of small cells having neuroendocrine features in terms of morphology, argyrophil property, and immunoreactivity for neuron-specific enolase. Mitomycin C, cisplatin, and cyclophosphamide were judged to be effective against both strains. Particularly, cisplatin produced almost complete regression of tumour growth of the TEG13 strain. Etoposide proved effective only against the TSG15 strain. Moreover, the combined treatment with etoposide and cisplatin produced the most pronounced antitumour effect against the TSG15 strain. These studies suggest that cisplatin may be a key drug for chemotherapy of oesophageal SCC, and etoposide plus cisplatin treatment may be especially recommended in the treatment of gastric SCC. Mitomycin C should be re-evaluated in gastrointestinal SCC.
我们建立了两株源自食管或胃的小细胞癌（SCC）异种移植物，命名为TEG13和TSG15，并研究了这些品系对实验性化疗的反应。两种肿瘤在形态、嗜银性和神经元特异性烯醇化酶免疫反应性方面均被归类为具有神经内分泌特征的小细胞组成的中间细胞型SCC。丝裂霉素C、顺铂和环磷酰胺被判定对两种品系均有效。特别是，顺铂几乎使TEG13品系的肿瘤生长完全消退。依托泊苷仅对TSG15品系有效。此外，依托泊苷和顺铂联合治疗对TSG15品系产生了最显著的抗肿瘤作用。这些研究表明，顺铂可能是食管SCC化疗的关键药物，依托泊苷加顺铂治疗可能特别推荐用于胃SCC的治疗。丝裂霉素C在胃肠道SCC中应重新评估。
